<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00396162</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00006212</org_study_id>
    <nct_id>NCT00396162</nct_id>
  </id_info>
  <brief_title>Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis</brief_title>
  <official_title>Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Rosell</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <brief_summary>
    <textblock>
      Chronic sinusitis is reported to be one of the most widespread disorders in the United
      States. It can be caused by a variety of reasons such as allergy, infection and/or defects in
      T-cells which help regulate immune function. Medication and other costs related to treatment
      of nasal and sinus infections are estimated to be more than $60 million annually putting a
      considerable strain on the economy of health care.

      Probiotics are live microorganisms that are normally present in the gut of a healthy
      individual. They are also known as &quot;friendly bacteria&quot; and have been used to help maintain
      the normal functioning of the immune system. They are safe and are commercially available in
      the form of yoghurt, sachets, chewable tablets or flavored capsules. Since a number of nasal
      and sinus disorders are related to allergy and improper functioning of the immune system, we
      hypothesize that regular use of probiotics may help improve chronic nasal and sinus symptoms
      by boosting immune responses.

      The project we propose is novel because it would be the first study evaluating the usefulness
      of probiotics for the larger population having chronic sinusitis rather than those having
      only allergic symptoms. We aim to assess whether regular use of probiotics will help improve
      symptoms of chronic sinusitis and will have a greater effect than placebo in this regard.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics are live microorganisms which when administered in adequate amounts confer a
      health benefit on the host. They are a part of the normal gastrointestinal flora and have
      safely been used to boost immune responses in patients with perennial and seasonal allergic
      rhinitis. Their exact mechanism of benefit is unknown but they primarily help to regulate
      T-cell function which is important in maintaining immune tolerance.

      Chronic rhinosinusitis is widely prevalent and affects nearly 16 million people in the US
      alone each year. It puts a strain on the health resources of the nation in terms of costs
      related to medications and surgery. Chronic rhinosinusitis can be caused by a variety of
      reasons including allergy/hypersensitivity, infection, nasal anatomical variations and T-cell
      regulatory dysfunction. We hypothesize that regular use of probiotics in patients with
      chronic rhinosinusitis will result in substantial improvement in their symptoms by boosting
      their immunity and may also help decrease their medication usage.

      Our study will be a double-blinded, randomized, control trial. We hope to recruit 100
      patients from the University Otolaryngology and Allergy Clinics. Fifty patients will be
      randomized to the treatment (active) arm and 50 patients to the placebo arm. Subjects will be
      followed for 2 months during their period of participation in the study.

      The main aim of our study is to determine whether regular use of probiotics in patients with
      chronic rhinosinusitis helps improve their quality of life. Our main outcome of interest is a
      change in the mean score of the Sino-Nasal Outcome Test (SNOT-20) form in the treatment group
      and a greater change in the mean score of the SNOT-20 in the treatment arm as compared to the
      placebo arm. If probiotics are found to be effective, they may be used as a cost-effective,
      adjunctive therapy for patients with chronic rhinosinusitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Reduction in SNOT-20 Scores</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side Effect Summary</measure>
    <time_frame>8 weeks</time_frame>
    <description>Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)</measure>
    <time_frame>At 8 weeks after baseline measures</time_frame>
    <description>Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Days of Steroid Spray Use for Each Group</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Chronic Rhinosinusitis</condition>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pills on same schedule as active intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L. rhamnosus R0011 strain</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>probiotic containing L.rhamnosus R0011 strain</intervention_name>
    <description>500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>L rhamnosus R0011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo pill</description>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥15 and ≤70 years.

          2. The patient must be bothered by each of the two following symptoms(&gt;50% of days in the
             last 3 months):

             A. More than 12 consecutive weeks of symptomatic nasal obstruction and, B. More than
             12 weeks of symptomatic nasal discharge.

          3. An Otolaryngologist evaluation and diagnosis of chronic inflammatory rhinosinusitis
             (hyperplastic mucosa, polyps in absence of overt bacterial infection)

          4. Access to telephone (home or person cell).

        Exclusion Criteria:

          1. Sinus surgery within the last 3 months

          2. Acute illness within the last 2 weeks requiring antibiotics: including: otitis media,
             pharyngitis, bronchitis, or laryngitis.

          3. Immunosuppression (due to medications including oral steroids, or due to autoimmune
             diseases, HIV infection, cystic fibrosis, immunodeficiency, malignancies, uncontrolled
             diabetes mellitus, chronic renal failure, etc.)

          4. Patients with chronic or acute bacterial sinusitis.(Clinical diagnosis-to be decided
             by MD)

          5. An allergic reaction to a probiotic dietary supplement in the past (such as symptoms
             of tightness in the chest, breathing difficulties, skin hives, rash or other clinical
             symptoms consistent with sensitivity or intolerance)

          6. Inability to speak or read English.

          7. Pregnancy and Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey E Terrell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2006</study_first_submitted>
  <study_first_submitted_qc>November 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2006</study_first_posted>
  <results_first_submitted>May 28, 2015</results_first_submitted>
  <results_first_submitted_qc>June 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2016</results_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Jeffrey E. Terrell, M.D.</investigator_full_name>
    <investigator_title>Professor of Otolaryngology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>82 participants were screened . 77 enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Probiotic</title>
          <description>The study protocol scheduled daily oral supplementation of either the probiotic or the placebo twice daily for four weeks. The probiotic product was a chewable tablet containing 500 million active cells of L rhamnosus R0011 strain per tablet. Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Probiotic</title>
          <description>drug
probiotic containing L.rhamnosus R0011 strain: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Pill</title>
          <description>Placebo pills on same schedule as active intervention.
probiotic containing L.rhamnosus R0011 strain: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="12.6"/>
                    <measurement group_id="B2" value="49.6" spread="8.6"/>
                    <measurement group_id="B3" value="49.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>asthma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>intermittent and mild asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate-severe asthma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>aspirin sensitivity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Aspirin Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No aspirin sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SinoNasal Outcome Test Score (SNOT-20)</title>
          <description>SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="16.2"/>
                    <measurement group_id="B2" value="39.5" spread="19.8"/>
                    <measurement group_id="B3" value="37.9" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Reduction in SNOT-20 Scores</title>
        <description>Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotic</title>
            <description>The study protocol scheduled daily oral supplementation of either the probiotic or the placebo twice daily for four weeks. The probiotic product was a chewable tablet containing 500 million active cells of L rhamnosus R0011 strain per tablet. Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction in SNOT-20 Scores</title>
          <description>Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="12"/>
                    <measurement group_id="O2" value="5.5" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effect Summary</title>
        <description>Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.</description>
        <time_frame>8 weeks</time_frame>
        <population>The sample size on the placebo side is reduced due to some study participants not reporting their 8 week survey</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Pill</title>
            <description>Placebo pills on same schedule as active intervention.
Placebo: Placebo pill</description>
          </group>
          <group group_id="O2">
            <title>Probiotic</title>
            <description>L. rhamnosus R0011 strain
probiotic containing L.rhamnosus R0011 strain: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effect Summary</title>
          <description>Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.</description>
          <population>The sample size on the placebo side is reduced due to some study participants not reporting their 8 week survey</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.31</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)</title>
        <description>Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)</description>
        <time_frame>At 8 weeks after baseline measures</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
          <group group_id="O2">
            <title>Active Intervention</title>
            <description>The study protocol scheduled daily oral supplementation of either the probiotic or the placebo twice daily for four weeks. The probiotic product was a chewable tablet containing 500 million active cells of L rhamnosus R0011 strain per tablet. Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)</title>
          <description>Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="5.5"/>
                    <measurement group_id="O2" value="0.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Days of Steroid Spray Use for Each Group</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Probiotic</title>
            <description>The study protocol scheduled daily oral supplementation of either the probiotic or the placebo twice daily for four weeks. The probiotic product was a chewable tablet containing 500 million active cells of L rhamnosus R0011 strain per tablet. Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Days of Steroid Spray Use for Each Group</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="7.4"/>
                    <measurement group_id="O2" value="0.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active Intervention</title>
          <description>The study protocol scheduled daily oral supplementation of either the probiotic or the placebo twice daily for four weeks. The probiotic product was a chewable tablet containing 500 million active cells of L rhamnosus R0011 strain per tablet. Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablets comparable to the probiotic in color, weight, texture, and flavor were also available.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bloating</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>loose stools</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jeffrey E. Terrell</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734 936 7633</phone>
      <email>terrelj@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

